We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+26.51%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.37B
AUM Growth
-$51.4M
Cap. Flow
-$112M
Cap. Flow %
-4.71%
Top 10 Hldgs %
45.23%
Holding
88
New
8
Increased
6
Reduced
18
Closed
10

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$105M
2
ZYME icon
Zymeworks
ZYME
+$41.2M
3
IMVT icon
Immunovant
IMVT
+$32.2M
4
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$26.6M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$15.1M

Top Sells

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$76.9M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$73.7M
3
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$43.1M
4
NUVL
Nuvalent
NUVL
+$32.4M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$29.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRDN icon
26
Viridian Therapeutics
VRDN
$2.11B
$36.2M 1.53%
1,238,974
-502,866
-29% -$11.6M
ITOS
27
DELISTED
iTeos Therapeutics
ITOS
$35.4M 1.49%
1,810,835
– –
LXRX icon
28
Lexicon Pharmaceuticals
LXRX
$1.03B
$30.8M 1.3%
16,149,179
– –
CBIO
29
Crescent Biopharma
CBIO
$523M
$28.9M 1.22%
95,443
– –
RAIN
30
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$28.2M 1.19%
3,526,729
– –
STRO icon
31
Sutro Biopharma
STRO
$402M
$27.1M 1.14%
334,795
-10,000
-3% -$695K
SLN
32
Silence Therapeutics
SLN
$527M
$23M 0.97%
1,508,416
– –
VIGL
33
DELISTED
Vigil Neuroscience
VIGL
$22.7M 0.96%
1,813,633
– –
EPIX
34
DELISTED
ESSA Pharma
EPIX
$22M 0.93%
8,748,629
– –
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
$21.4M 0.9%
6,894,345
– –
CNCE
36
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$21.2M 0.89%
3,629,000
– –
ANNX icon
37
Annexon
ANNX
$834M
$19.5M 0.82%
3,780,694
– –
JANX icon
38
Janux Therapeutics
JANX
$923M
$19.4M 0.82%
1,470,334
– –
TYRA icon
39
Tyra Biosciences
TYRA
$1.88B
$18.8M 0.79%
2,472,327
– –
THRD
40
DELISTED
Third Harmonic Bio
THRD
$18.8M 0.79%
4,365,933
+864,119
+25% +$14.5M
OLMA icon
41
Olema Pharmaceuticals
OLMA
$1.01B
$18.6M 0.79%
7,611,503
– –
NAMS icon
42
NewAmsterdam Pharma
NAMS
$3.23B
$16M 0.68%
+1,521,948
New +$15.1M
ACIU icon
43
AC Immune
ACIU
$227M
$15.2M 0.64%
7,428,379
– –
ANTX icon
44
AN2 Therapeutics
ANTX
$194M
$14.9M 0.63%
1,563,963
-52,702
-3% -$706K
CALT
45
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$13.1M 0.55%
750,000
– –
OVID icon
46
Ovid Therapeutics
OVID
$418M
$12.7M 0.54%
6,851,051
– –
VERV
47
DELISTED
Verve Therapeutics
VERV
$12.6M 0.53%
650,000
– –
COGT icon
48
Cogent Biosciences
COGT
$6.72B
$11.4M 0.48%
984,824
-1,100,000
-53% -$13.6M
CTMX icon
49
CytomX Therapeutics
CTMX
$686M
$10.6M 0.45%
6,595,801
– –
ALPN
50
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.35M 0.35%
1,135,940
– –
1
2
3 4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2022 Portfolio in Review

As of Q4 2022, BVF Inc held 88 positions worth $2.37B, down 2.1% from $2.42B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

BVF Inc withdrew a net $112M in Q4 2022, closing 10 positions and reducing 18 holdings. Its most notable exit was Relmada Therapeutics, an estimated $76.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, BVF Inc opened a new position in Axsome Therapeutics worth $135M.

  • BVF Inc's largest Q4 2022 buy was Axsome Therapeutics: 1,755,000 shares worth $135M.
  • BVF Inc added most to POINT Biopharma Global Inc. Common Stock in Q4 2022, an estimated $26.6M increase.
  • BVF Inc's biggest Q4 2022 reduction was Ionis Pharmaceuticals, cutting an estimated $73.7M.
  • BVF Inc fully exited Relmada Therapeutics in Q4 2022, selling an estimated $76.9M.
  • BVF Inc's ten largest holdings make up 45% of its $2.37B portfolio in Q4 2022.
  • BVF Inc opened 8 new positions and closed 10 in Q4 2022.
  • BVF Inc's portfolio value fell 2.1% quarter-over-quarter to $2.37B.

Based on BVF Inc's 13F filing for Q4 2022, filed 14 Feb 2023.